Three common medications lower risk and mortality for lung cancer

DENVER–Combined use of aspirin, statins, and metformin is associated with decreased lung cancer
incidence and mortality, according to a study published in the

Journal of Thoracic Oncology (JTO)

. The JTO is the official journal of the International Association for the Study of Lung Cancer.

All three medications are common–approximately 35 million people take a statin to control cholesterol; more than 120 million people take metformin to control diabetes and between 6 and 10 million people take aspirin daily.

The aim of this study was to investigate the associations of aspirin, metformin, and
statins with lung cancer risk and mortality using population-based nationwide cohort data from

The Korean National Health Insurance Services (KNHIS) database was used in the present study. The KNHIS is a universal health care system that covers the entire Korean population of 50 million.

“To our knowledge, no study has evaluated aspirin, statins, and metformin use and their combined impact on lung cancer incidence and mortality,” said lead study author Dong Wook Shin, MD, DrPH, MBA at the Sungkyunkwan University School of Medicine in Seoul, Korean.

Dr. Shin and his colleagues (Dr. Jihun Kang and Dr. Su-Min Jeong) examined 732,199 Koreans from the Korean National Health Insurance Services database. The patients were followed between January 2004 and December 2013. Lung cancer incidence and mortality were identified using a registered lung cancer diagnosis code (ICD-10 code C34) and the Korean National Death Registry.

To address the combined associations of these cardiovascular drugs with lung cancer risk and
mortality, the researchers categorized the cohort into eight groups, based on exposure to aspirin, statins, and metformin.

Combined use of aspirin, statins, and metformin was associated with decreased lung cancer
incidence (aHR 0.83, 95% CI, 0.69-0.99) and mortality (aHR 0.83, 95% CI, 0.70-0.99) compared with
non-users.

“When these cardiovascular drugs were used in combination, their protective associations with lung cancer risk and related mortality were augmented and the magnitude of effect increased with increasing duration of medication use,” said Dr. Shin.

During 2012-2013 period (the most recent period in the study), study participants taking all three medications were 3.4% (23,163 out of 676,520).

“Interestingly, the inverse association of combined use of aspirin, statins, and metformin was
prominent, and the longer the duration of combined use, the more protective the association.
This finding is in line with a study demonstrating that aspirin and metformin synergistically inhibit lung
cancer cell proliferation by activating AMP activated protein kinase, which plays a critical role in
regulation of lipogenesis in cancer cells,” Dr. Shin wrote.

Dr. Shin theorized that concomitant use of aspirin, statins, and metformin concurrently inhibits multiple pathways related to lung cancer cell growth and proliferation resulting in favorable associations with lung cancer risk and mortality.

###


About the IASLC

The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association’s membership includes nearly 9,000 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the

Journal of Thoracic Oncology

, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies. Visit

http://www.

iaslc.

org

for more information.



About the

JTO


Journal of Thoracic Oncology (JTO),

the official journal of the International Association for the Study of Lung Cancer, is the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies.

JTO

emphasizes a multidisciplinary approach and includes original research reviews and opinion pieces. The audience includes epidemiologists, medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists, radiologists, pathologists, nuclear medicine physicians, and research scientists with a special interest in thoracic oncology.

This part of information is sourced from https://www.eurekalert.org/pub_releases/2020-09/iaft-tcm091520.php